AYTUAYTUHealthcare · Drug Manufacturers - Specialty & Generic

AYTU Stock Forecast: Aytu Biopharma, Inc. Price Predictions for 2026-2027

Last close, 12 Aug 2026
$2.36
−1.69% on the day

The 3 Wall Street analysts covering Aytu Biopharma, Inc. hold a median 12-month price target of $7 — +196.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 62 of 100 as at 12 Aug 2026 — in the upper half.

Market cap
$25.3M
Ticker Nerd rank
62 / 100
Median analyst target
$7.00
Analysts covering
3
Total return, dividends reinvested
1W
+2.6%
1M
+4.9%
YTD
−9.2%
1Y
+4.9%
From 52W high
−18.6%
From 52W low
+38.0%
$1.71
$2.90
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AYTU stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Aytu Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Aug 2026
62 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
97
Volatility
92
Size
87
Quality
77
Value
55
Momentum
49
Revisions
39
Growth
20
Issuance
19

Accruals (97): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (19): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AYTU stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AYTU, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Oct 25Jan 26Apr 26Jul 26AYTUHigh $14.50Median $7.00Low $7.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $7.00Median $7.00High $14.50

The green dot is the last close — the median target sits +196.6% from it.

Recent analyst actionsNewest first

Of the 16 most recent actions, 1 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
11 June 2026Ascendiant CapitalMaintainsBuy$14$15
10 Dec 2025Ascendiant CapitalMaintainsBuy
25 Sept 2025Ascendiant CapitalMaintainsBuy
25 Sept 2025Maxim GroupMaintainsBuy
1 July 2025Lake StreetInitiatesBuy
30 June 2025Ascendiant CapitalInitiatesBuy
9 Aug 2023Maxim GroupInitiatesBuy
31 May 2023HC Wainwright & Co.ReiteratesBuy
21 July 2022HC Wainwright & Co.MaintainsBuy$11$6.00
17 May 2022Cantor FitzgeraldMaintainsOverweight$11$5.00
28 Apr 2022HC Wainwright & Co.MaintainsBuy$24$11
30 Mar 2021Cantor FitzgeraldInitiatesOverweight
25 Nov 2020HC Wainwright & Co.InitiatesBuy
25 Nov 2020Northland SecuritiesInitiatesOutperform
29 May 2020HC Wainwright & Co.InitiatesBuy
22 Oct 2018Northland SecuritiesInitiatesOutperform

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AYTU appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

AYTU analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Aytu Biopharma, Inc. (AYTU) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.1×

Cheaper than 82% of US stocks

Price / sales
0.4×

Cheaper than 85% of US stocks

Price / book
0.7×

Cheaper than 80% of US stocks

EV / EBITDA
−8.4×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
−32.7%

Higher than 8% of US stocks

Earnings growth (YoY)
−32.7%

Higher than 14% of US stocks

Gross margin
61.2%

Higher than 75% of US stocks

Operating margin
−32.7%

Higher than 19% of US stocks

Net margin
−60.2%

Higher than 9% of US stocks

Returns & dividend
Return on equity
−97.4%

Higher than 13% of US stocks

Return on assets
−3.7%

Higher than 33% of US stocks

Dividend yield

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

AYTU vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
AYTUAytu Biopharma, Inc.$25.3M
62
OPTHOptimi Health Corp.$26.0M
10
TXMDTherapeuticsMD, Inc.$24.1M
77
RMTIRockwell Medical, Inc.$29.6M
58
UPCUniverse Pharmaceuticals, Inc.$30.4M
32
BTAIBioXcel Therapeutics, Inc.$32.7M
29
IXHLIncannex Healthcare, Inc.$37.9M
23

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Aytu Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Frequently asked questions about AYTU stock

What is the AYTU stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Aytu Biopharma, Inc. have a median 12-month price target of $7, with estimates ranging from $7 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AYTU stock a buy right now?

Of the 3 analysts covering Aytu Biopharma, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aytu Biopharma, Inc. 62 out of 100 across roughly 4,600 US stocks as at 12 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AYTU?

As at 12 Aug 2026, Aytu Biopharma, Inc. ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (97 of 100).

Will AYTU stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +196.6% from the last close, and Ticker Nerd's factor model ranks Aytu Biopharma, Inc. 62 out of 100 as at 12 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AYTU stock forecast for 2030?

No analyst covering Aytu Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AYTU are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $15 over the next 12 months.

How has AYTU stock performed over the past year?

Aytu Biopharma, Inc. returned +4.9% over the 12 months to 12 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Aytu Biopharma, Inc. do?

Aytu BioPharma Inc. is a specialty pharmaceutical company focused on advancing innovative medicines for complex central nervous system (CNS) diseases, including major depressive disorder (MDD) and attention deficit hyperactivity disorder (ADHD), to improve patient quality of life.

Company

About Aytu Biopharma, Inc.

Aytu BioPharma Inc. is a specialty pharmaceutical company focused on advancing innovative medicines for complex central nervous system (CNS) diseases, including major depressive disorder (MDD) and attention deficit hyperactivity disorder (ADHD), to improve patient quality of life. Its prescription portfolio features EXXUA (gepirone) extended-release tablets, the first and only FDA-approved selective serotonin 5HT1a receptor agonist for treating MDD in adults, alongside an ADHD portfolio with products like Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The company also markets a pediatric portfolio of legacy products such as Karbinal ER (carbinoxamine maleate), Poly-Vi-Flor, and Tri-Vi-Flor, addressing common pediatric conditions. Aytu BioPharma Inc. operates primarily through prescription pharmaceutical products sold via third parties and patient access programs like RxConnect pharmacies. Founded in 2002 and headquartered in Denver, Colorado, it plays a role in the pharmaceutical sector by commercializing novel therapeutics in CNS and related therapeutic areas.

CEO Mr. Joshua R. Disbrow · 82 employees · United States · https://aytubio.com